The stock of Loxo Oncology Inc (NASDAQ:LOXO) is a huge mover today! About 133,830 shares traded hands or 70.52% up from the average. Loxo Oncology Inc (NASDAQ:LOXO) has risen 11.33% since April 14, 2016 and is uptrending. It has outperformed by 6.64% the S&P500.
The move comes after 6 months negative chart setup for the $584.30M company. It was reported on Nov, 16 by Barchart.com. We have $25.11 PT which if reached, will make NASDAQ:LOXO worth $40.90 million less.
Loxo Oncology Inc (NASDAQ:LOXO) Ratings Coverage
Out of 3 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 2 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive. Loxo Oncology Inc has been the topic of 11 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Citigroup initiated Loxo Oncology Inc (NASDAQ:LOXO) on Monday, January 18 with “Buy” rating. Cowen & Co maintained Loxo Oncology Inc (NASDAQ:LOXO) on Thursday, August 27 with “Outperform” rating. The stock of Loxo Oncology Inc (NASDAQ:LOXO) earned “Sell” rating by Zacks on Friday, August 28. Stifel Nicolaus maintained Loxo Oncology Inc (NASDAQ:LOXO) rating on Wednesday, March 16. Stifel Nicolaus has “Buy” rating and $36 price target. Oppenheimer maintained the shares of LOXO in a report on Tuesday, August 4 with “Buy” rating. On Friday, January 15 the stock rating was initiated by Citigroup with “Buy”. The company was maintained on Wednesday, November 11 by Stifel Nicolaus. The company was maintained on Wednesday, March 16 by Citigroup.
According to Zacks Investment Research, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.”
Insitutional Activity: The institutional sentiment increased to 2.82 in Q2 2016. Its up 1.46, from 1.36 in 2016Q1. The ratio is positive, as 6 funds sold all Loxo Oncology Inc shares owned while 11 reduced positions. 12 funds bought stakes while 36 increased positions. They now own 20.32 million shares or 11.63% more from 18.21 million shares in 2016Q1.
Eam Investors Ltd Llc holds 0.7% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO) for 199,730 shares. Legal General Group Public Limited Co has invested 0% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO). Moreover, Axa has 0.03% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 260,412 shares. Aqr Capital Mngmt Ltd Liability Co reported 14,272 shares or 0% of all its holdings. The California-based Nicholas Prtnrs Limited Partnership has invested 0.11% in Loxo Oncology Inc (NASDAQ:LOXO). Driehaus Cap Management Limited Liability Co accumulated 0.26% or 315,024 shares. Strs Ohio holds 11,200 shares or 0% of its portfolio. Barclays Public Limited Liability Company has 0% invested in the company for 2,664 shares. Bridgeway Cap Mgmt owns 30,250 shares or 0.01% of their US portfolio. Retail Bank Of America De holds 0% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO) for 2,729 shares. State Street Corporation, a Massachusetts-based fund reported 201,021 shares. Citigroup Incorporated accumulated 1,413 shares or 0% of the stock. Moreover, Deerfield Management has 0.23% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 251,000 shares. Swiss State Bank holds 20,200 shares or 0% of its portfolio. Baker Bros Advisors L P, a New York-based fund reported 137,735 shares.
Insider Transactions: Since May 17, 2016, the stock had 0 buys, and 4 sales for $24.97 million net activity. On Thursday, August 11 Flaherty Keith T. sold $389,967 worth of the stock or 15,000 shares. AISLING CAPITAL III LP had bought 232,558 shares worth $5.00 million. $12.07 million worth of Loxo Oncology Inc (NASDAQ:LOXO) was sold by Bonita David P on Wednesday, August 10. Another trade for 447,857 shares valued at $12.07 million was made by ORBIMED ADVISORS LLC on Wednesday, August 10.
More recent Loxo Oncology Inc (NASDAQ:LOXO) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on August 01, 2014. Also Quotes.Wsj.com published the news titled: “News Loxo Oncology Inc.LOXO” on August 01, 2014. Globenewswire.com‘s news article titled: “Loxo Oncology Announces Second Quarter 2016 Financial Results” with publication date: August 03, 2016 was also an interesting one.
LOXO Company Profile
Loxo Oncology, Inc., incorporated on May 9, 2013, is a biopharmaceutical company. The Firm is engaged in the development of selective medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. LOXO-101 is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family that it is developing for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma and breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.